RxDoctor Payments Data

Tristan Strong

Primary Care · Nolensville, TNNPI 1134690910

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $831, more than ten times the $16 reported in 2021.

$1,733in general payments, 2019–2025

Across 87 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$274
  • Astellas Pharma US Inc$193
  • Indivior Inc.$171
  • Boston Scientific$156
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$139
  • Braeburn Inc.$136
  • plus $663 from 16 others

What the payments were for

  • Food & beverage$1,733100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,733 in reported general payments places this provider in the 70th percentile of 189 primary care providers in Tennessee.

See all primary care providers in Tennessee

Medicare billing

Part B allowed, 2024
$39,942
Medicare patients
174
Services billed
3,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$29,575
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$26,224
EliquisApixaban28$15,992
GemtesaVibegron14$13,868
SymbicortBudesonide/Formoterol Fumarate14$3,316
Atorvastatin Calcium135$1,663
Albuterol Sulfate HfaAlbuterol Sulfate43$1,378
Clonidine13$1,262
Losartan Potassium78$1,088
Bupropion XlBupropion Hcl17$859
Gabapentin66$753
Potassium Chloride33$752
Levothyroxine Sodium102$736
Omeprazole46$698
Pantoprazole Sodium51$670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$63$29,57528 claims
GSKTrelegy Ellipta$70$26,22436 claims
Sumitomo Pharma America, Inc.Gemtesa$34$13,86814 claims
AstraZenecaSymbicort$45$3,31614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 189 primary care providers in Tennessee.

Other primary care in Nolensville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →